Abstract
BACKGROUND: The TAXUS NIRx stent (Boston Scientific Corp) provides local delivery of paclitaxel via a slow-release polymer coating. The TAXUS I trial was the first in-human experience evaluating safety and feasibility of the TAXUS NIRx stent system compared with bare NIR stents (control) (Boston Scientific Corp) for treatment of coronary lesions. METHODS AND RESULTS: The TAXUS I trial was a prospective, double-blind, three-center study randomizing 61 patients with de novo or restenotic lesions (
Citation impact
- FWCI
- 95.96
- Percentile
- 100%
- References
- 12
Authors
7- EGEberhard GrubeCorresponding
Boston Scientific (United States), Krankenhaus Barmherzige Brüder
- SSSigmund Silber
Boston Scientific (United States), Krankenhaus Barmherzige Brüder
- KEKarl Eugen Hauptmann
Boston Scientific (United States), Krankenhaus Barmherzige Brüder
- RMRalf Mueller
Boston Scientific (United States), Krankenhaus Barmherzige Brüder
- LBLutz Buellesfeld
Boston Scientific (United States), Krankenhaus Barmherzige Brüder
Topics & keywords
- Mace
- Medicine
- Taxus
- Restenosis
- Neointimal hyperplasia
- Stent
- Lumen (anatomy)
- Paclitaxel
- Good health and well-being